Efalizumab
- Generic Name
- Efalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 214745-43-4
- Unique Ingredient Identifier
- XX2MN88N5D
- Background
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a poten...
- Indication
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
- Associated Conditions
- Moderate to Severe Chronic Plaque Psoriasis
- Associated Therapies
- -
Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT00777400
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Efalizumab in the Treatment of Alopecia, Phase II
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00746980
Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Emory University
- Registration Number
- NCT00737763
A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00729768
Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT00676559
- Locations
- 🇺🇸
Sharp Rees-Stealy Medical Group, San Diego, California, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Eye Care Specialists, Kingston, Pennsylvania, United States
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT00669214
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT00472082
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
- Conditions
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Registration Number
- NCT00442650
- Locations
- 🇨ðŸ‡
Merck Serono Medical Information Office, Geneva, Switzerland
A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies
- Conditions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1200
- Registration Number
- NCT00338143
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT00336973
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.